ECHELON-1 study of brentuximab vedotin as frontline therapy for Hodgkin's lymphoma

Bookmark and Share
Published: 10 Dec 2017
Views: 2582
Dr Joseph Connors - British Columbia Cancer Agency, Vancouver, Canada

Dr Connors speaks with ecancer at the 2017 ASH annual meeting about the phase 3 ECHELON-1 study looking at brentuximab vedotin plus doxorubicin, vinblastine, dacarbazine as frontline therapy in patients with previously untreated stage III or IV hodgkin lymphoma.

Read the news story or watch the press conference for more.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.